Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
暂无分享,去创建一个
A. Papenfuss | G. McArthur | J. Oliaro | S. Mangiola | C. Cullinane | L. Martelotto | K. Sheppard | N. Haynes | Laura Kirby | Emily J. Lelliott | Claire A Martin | P. Lau | A. Oliver | A. Slater | K. Ramsbottom | Magnus Zethoven | Lydia Lim | Riyaben P. Patel | Claire A. Martin
[1] E. Alnemri,et al. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. , 2019, Cancer discovery.
[2] Howard Y. Chang,et al. Clonal replacement of tumor-specific T cells following PD-1 blockade , 2019, Nature Medicine.
[3] Rui Hou,et al. scMatch: a single-cell gene expression profile annotation tool using reference datasets , 2019, Bioinform..
[4] F. Hodi,et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade , 2019, Nature Immunology.
[5] F. Souza-Fonseca-Guimaraes,et al. A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy , 2019, Scientific Reports.
[6] Atul J. Butte,et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.
[7] Lai Guan Ng,et al. Dimensionality reduction for visualizing single-cell data using UMAP , 2018, Nature Biotechnology.
[8] M. Diamond,et al. WDFY4 is required for cross-presentation in response to viral and tumor antigens , 2018, Science.
[9] Christoph Hafemeister,et al. Comprehensive integration of single cell data , 2018, bioRxiv.
[10] Paul J. Hoover,et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma , 2018, Cell.
[11] J. Allison,et al. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.
[12] R. Pearson,et al. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance , 2018, International journal of cancer.
[13] Adrian V. Lee,et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.
[14] C. Paweletz,et al. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. , 2017, Cancer discovery.
[15] J. Liu,et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor , 2017, Nature Immunology.
[16] M. Ellis,et al. CDK4/6 inhibition triggers anti-tumor immunity , 2017, Nature.
[17] Jedd D. Wolchok,et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.
[18] Roland Eils,et al. Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..
[19] F. Ginhoux,et al. Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. , 2016, Immunity.
[20] Gianluca Bontempi,et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.
[21] J. Utikal,et al. Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab , 2015, Clinical Cancer Research.
[22] A. Trautmann,et al. Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site , 2015, Oncotarget.
[23] J. Wolchok,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[24] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[25] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.
[26] G. Freeman,et al. Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade , 2014, Cancer Immunology Research.
[27] T. Burke,et al. The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation , 2013, Molecular Cancer Therapeutics.
[28] Sebastian Amigorena,et al. Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. , 2014, Cancer cell.
[29] G. McArthur,et al. The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma , 2013, Clinical Cancer Research.
[30] R. Sullivan,et al. BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.
[31] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[32] H. Mages,et al. Expression of XCR1 Characterizes the Batf3-Dependent Lineage of Dendritic Cells Capable of Antigen Cross-Presentation , 2012, Front. Immun..
[33] J. Wilmott,et al. Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma , 2011, Clinical Cancer Research.
[34] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[35] K. Flaherty,et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.
[36] E. Birney,et al. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt , 2009, Nature Protocols.
[37] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[38] L. Zitvogel,et al. Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.
[39] P. Grambsch,et al. A Package for Survival Analysis in S , 1994 .
[40] Elizabeth Brunk,et al. Antigen receptor repertoire profiling from RNA-seq data , 2022 .